GeneDx Holdings Corp. (WGS)
| Market Cap | 3.45B |
| Revenue (ttm) | 362.32M |
| Net Income (ttm) | 1.41M |
| Shares Out | 28.73M |
| EPS (ttm) | 0.05 |
| PE Ratio | 2,480.04 |
| Forward PE | 56.06 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 514,524 |
| Open | 119.66 |
| Previous Close | 118.26 |
| Day's Range | 118.00 - 123.51 |
| 52-Week Range | 48.95 - 136.00 |
| Beta | 2.04 |
| Analysts | Strong Buy |
| Price Target | 102.14 (-15.02%) |
| Earnings Date | Oct 28, 2025 |
About WGS
GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company also develops an AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. The company is headquartered in Stamford, Connecticut. [Read more]
Financial Performance
In 2024, GeneDx Holdings's revenue was $305.45 million, an increase of 50.79% compared to the previous year's $202.57 million. Losses were -$52.29 million, -70.25% less than in 2023.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for WGS stock is "Strong Buy." The 12-month stock price target is $102.14, which is a decrease of -15.02% from the latest price.
News
GeneDx Announces First U.S. National Genomic Newborn Screening Initiative Launched with $14.4 Million NIH Award
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced the launch of BEACONS, the nation's first multi-state genomic newborn screening initiative.
GeneDx Appoints Lisa Gurry as Chief Business Officer to Unlock Data and Information Growth
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced the appointment of Lisa Gurry as Chief Business Officer, effective immediately.
GeneDx Infinity™ Pioneers a New Era of Genetic Medicine with its Introduction at the American Academy of Pediatrics National Conference
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will introduce pediatricians to GeneDx's Infinity...
GeneDx Appoints Visionary AI and Precision Medicine Leader Dr. Thomas Fuchs to Board of Directors
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Appoints Visionary AI and Precision Medicine Leader Dr. Thomas Fuchs to Board of Directors.
GeneDx Holdings Corp. (WGS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
GeneDx Holdings Corp. (NASDAQ:WGS) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 8:30 AM EDT Company Participants Katherine Stueland - President, CEO & Director Kevin Feel...
Seer Appoints Isaac Ro to its Board of Directors
REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced it has appointed Isaac Ro to ...
Scott+Scott Attorneys at Law LLP Alerts Investors to Its Investigation Into GeneDx Holdings Corp. (NASDAQ: WGS)
NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder litigation firm, alerts investors that it is investigating whether GeneDx Holdings Corp. (“G...
GeneDx to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that company management will participate in upcoming investor conferences.
GeneDx Surges Past Q2 Expectations, Sets Up For Strong Year-End Growth
GeneDx delivered a strong Q2 2025, with revenues and earnings beating expectations and full-year guidance raised over 10%. Revenue growth is driven by higher testing volumes, improved reimbursement ra...
WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Investigation With the DJS Law Group
LOS ANGELES , July 31, 2025 /PRNewswire/ -- News provided by DJS Law Group LLP The DJS Law Group reminds investors that it is investigating claims GeneDx Holdings Corp. ("GeneDx" or "the Company") (NA...
GeneDx Holdings Corp. Investors: Company Investigated by the Portnoy Law Firm
LOS ANGELES, July 30, 2025 (GLOBE NEWSWIRE) -- Investors can contact the law firm at no cost to learn more about recovering their losses
GeneDx CEO on rare disease diagnosis: Earlier testing gives families and clinicians more options
Katherine Stueland, GeneDx CEO, joins 'Squawk Box' to discuss diagnosing children with rare diseases, cost structure of the tests, the fight against rare diseases, company growth outlook, deployment o...
GeneDx Holdings Corp. (WGS) Q2 2025 Earnings Call Transcript
GeneDx Holdings Corp. (NASDAQ:WGS) Q2 2025 Earnings Conference Call July 29, 2025 8:00 AM ET Company Participants Katherine A. Stueland - President, CEO & Director Kevin Feeley - Chief Financial Offi...
GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the second quarter of 2025.
WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Fraud Investigation with the Schall Law Firm
LOS ANGELES , July 28, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of GeneDx Holdings Corp...
GeneDx: Strong Testing Volume And An Invaluable Genomic Database
GeneDx leverages a vast rare disease database and advanced genomic testing, offering superior insights over traditional panel testing. The company achieved a significant turnaround, becoming cash flow...
GeneDx to Report Second Quarter 2025 Financial Results on Tuesday, July 29, 2025
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) announced it will release financial results for the second quarter of 2025 before the market opens on Tuesday, July 29, 2025.
GeneDx Announces Publication of SeqFirst Study Demonstrating Need for First Tier Rapid Genomic Testing for Non-Critical Care Pediatric Inpatients in The Journal of Pediatrics
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced new data from the SeqFirst study team conducted in p...
GeneDx Announces American Academy of Pediatrics Recommends Exome and Genome Sequencing as First-Tier Tests for Children with Global Developmental Delay or Intellectual Disability
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announces the American Academy of Pediatrics (AAP) issued updated gu...
GeneDx Publishes Pioneering Vision for Applying AI to Genomics to Improve and Expedite Diagnosis of Genetic Disease at Scale
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announced the publication of a new article demonstrating the company's leadership in applying AI to accelerate and enhance genetic diagnostics.
GeneDx: Strong Fundamentals Intact As Market Misreads Test Volume Dip
GeneDx delivered strong Q1 2025 results, beating revenue and EPS estimates, and raised full-year guidance despite a minor sequential test volume dip. The volume decline is attributable to seasonality,...
GeneDx: Time To Buy The Dip
GeneDx's recent 50% stock drop post-Q1 earnings is seen as an overreaction, despite a projected modest growth slowdown from 42% to 30-35%. The company is expanding product lines, improving margins, an...
GeneDx Announces Completion of Fabric Genomics Acquisition
GAITHERSBURG, Md. & OAKLAND, Calif.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced the successful completion of its acquisition of Fabric Genomics, a pioneer in AI-powered genomic interpretati...
GeneDx Holdings Corp. (WGS) Q1 2025 Earnings Call Transcript
GeneDx Holdings Corp. (NASDAQ:WGS) Q1 2025 Earnings Conference Call April 30, 2025 8:30 AM ET Company Participants Sabrina Dunbar - Investor Relations Katherine Stueland - Chief Executive Officer Kev...
GeneDx Reports First Quarter 2025 Financial Results and Business Highlights
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the first quarter of 2025.